Abbott, an SJE Group investment, has appointed Robert B. Ford to take the reigns as CEO on March 31, 2020. At that time, Miles D. White will be stepping down from that role after a remarkable 21-year tenure; the second longest for a non-founder in today's S&P 100. Mr White will remain Executive Chairman of the Board.
Robert currently serves as President and Chief Operating Officer and has been elected to the Board. He will become the 13th CEO of Abbott in its 131-year history, all having been appointed from within the company.
Miles White was named Chairman and Chief Executive Officer in 1998. He has strategically reshaped Abbott several times, most recently building Abbott's leadership in medical devices and diagnostics with the additions of St. Jude Medical and Alere, and internal advances like FreeStyle Libre, the world's leading continuous glucose monitor, and the Alinity™ family of diagnostics systems.
Miles also spun out two highly successful companies, Hospira in 2004 (which was acquired by Pfizer in 2015), and AbbVie in 2013, which is a Fortune 100 company today. He spearheaded one of the most successful acquisitions in the pharmaceutical industry, purchasing BASF's Knoll pharmaceutical business in 2001. That transaction brought with it the industry-leading drug, Humira®1. Mr. White's bold strategic thinking and transformative actions have consistently made Abbott one of the world's most admired companies.
The SJE Group congratulates Robert Ford for his appointment and thanks Miles White for his exceptional service as CEO.